Multivariate analyses of 120 patients with available Ki-67 value according to outcome
| Variable . | Score . | Event-free survival, n = 115 . | Progression-free survival, n = 105 . | Survival, n = 115 . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Hazard ratio . | 95% CI . | P . | Hazard ratio . | 95% CI . | P . | Hazard ratio . | 95% CI . | P . | ||
| Ki-67 | 0-9/10-29/30+ | 1.96 | 1.19-3.23 | .008 | 1.77 | 0.95-3.30 | .074 | 1.17 | 0.57-2.43 | .663 |
| Cytologic variant | Common/blastoid | 1.19 | 0.59-2.40 | .631 | 0.85 | 0.33-2.19 | .735 | 2.70 | 1.31-5.50 | .014 |
| IPI | 0-2/3-5 | 1.28 | 0.67-2.42 | .451 | 0.81 | 0.35-1.88 | .624 | 2.62 | 1.29-5.32 | .007 |
| Growth pattern | Diffuse/nondiffuse | 1.61 | 0.84-3.08 | .149 | 1.42 | 0.65-3.11 | .381 | 2.07 | 0.97-4.41 | .059 |
| Sex | M/F | 0.74 | 0.36-1.5 | .429 | 0.23 | 0.05-0.95 | .041 | 0.58 | 0.23-1.44 | .243 |
| Age | ≤ 60/≥ 61 | 1.49 | 0.80-2.76 | .213 | 0.94 | 0.36-2.49 | .905 | 1.08 | 0.49-2.38 | .851 |
| Response to induction treatment | CR/PR | ND | 1.74 | 0.83-3.66 | .142 | ND | ||||
| Variable . | Score . | Event-free survival, n = 115 . | Progression-free survival, n = 105 . | Survival, n = 115 . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Hazard ratio . | 95% CI . | P . | Hazard ratio . | 95% CI . | P . | Hazard ratio . | 95% CI . | P . | ||
| Ki-67 | 0-9/10-29/30+ | 1.96 | 1.19-3.23 | .008 | 1.77 | 0.95-3.30 | .074 | 1.17 | 0.57-2.43 | .663 |
| Cytologic variant | Common/blastoid | 1.19 | 0.59-2.40 | .631 | 0.85 | 0.33-2.19 | .735 | 2.70 | 1.31-5.50 | .014 |
| IPI | 0-2/3-5 | 1.28 | 0.67-2.42 | .451 | 0.81 | 0.35-1.88 | .624 | 2.62 | 1.29-5.32 | .007 |
| Growth pattern | Diffuse/nondiffuse | 1.61 | 0.84-3.08 | .149 | 1.42 | 0.65-3.11 | .381 | 2.07 | 0.97-4.41 | .059 |
| Sex | M/F | 0.74 | 0.36-1.5 | .429 | 0.23 | 0.05-0.95 | .041 | 0.58 | 0.23-1.44 | .243 |
| Age | ≤ 60/≥ 61 | 1.49 | 0.80-2.76 | .213 | 0.94 | 0.36-2.49 | .905 | 1.08 | 0.49-2.38 | .851 |
| Response to induction treatment | CR/PR | ND | 1.74 | 0.83-3.66 | .142 | ND | ||||
CR indicates complete disappearance of all detectable disease manifestations; PR, at least 50% reduction of all evaluable disease manifestations; and ND, not determined.